SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the token's long-standing presence on the Solana network, with members highlighting active whale accumulation and organic engagement. Discussions are dominated by community members celebrating the project's recent trending status across market platforms and emphasizing the durability of a project that has maintained locked liquidity for over two years.

Chip

Chip is experiencing significant trading volatility following its recent listings on major platforms, sparking intense community debate over its utility in the AI infrastructure sector. While some investors are optimistic about its long-term potential as a governance token for GPU-backed financing, others are raising concerns about suspicious price action and the high volume of insider holdings.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is gaining momentum as investors anticipate major announcements at an upcoming industry conference, driving significant speculation about a potential breakout. The community remains deeply divided, with long-term believers accumulating shares on the expectation of utility-driven adoption while vocal critics dismiss the price action as a pump-and-dump cycle.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing a surge in social sentiment driven by ongoing community efforts to reduce circulating supply through consistent burn mechanisms and staking rewards. Investors are actively debating the token's potential for a long-term recovery, with many pointing to upcoming ecosystem projects and legislative developments as potential catalysts for future momentum.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding $UPDOG is actively highlighting the project's longevity on Solana and its presence on the Jupiter strict list, encouraging users to swap via JUP. Traders are also discussing broader market sentiment and utilizing JUP's lending features, despite some community frustration regarding exchange volatility and platform performance.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as the community remains sharply divided between long-term holders accumulating during the accumulation phase and vocal critics frustrated by stagnant price action and lack of communication from leadership. Discussions are heavily focused on the project's long-term utility in data ownership compared to newer ecosystem developments, with investors debating the impact of market cycles on their holdings.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain is trending following the announcement of a multi-million dollar contract to deploy its connectivity solutions across a major U.S. utility's vehicle fleet. Investors are actively debating the company's growth potential and its broader strategic partnerships within the wireless infrastructure and 5G sectors.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

Tron (TRX) is currently trending due to its growing utility as a primary infrastructure layer for stablecoin payments and significant integrations with major platforms like Rumble. The community is actively discussing its resilience in volatile market conditions and the strategic impact of its increasing adoption across global financial systems.

Tidal Trust II - Defiance Daily Target 2X Long IONQ ETF

Defiance Daily Target 2X Long IONQ ETF

IONX is trending as traders use the leveraged ETF to capitalize on high-volatility price swings in the underlying quantum computing sector. The community is actively debating the risks of holding the leveraged vehicle through market turbulence, focusing on technical support levels and potential for significant short-term gains.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The Roundhill Magnificent Seven ETF is trending as investors debate the sustainability of the AI capex cycle and watch for rotation into other sectors amidst broader market volatility. Community discussion is focused on the ETF's role as a proxy for Big Tech dominance, with some traders monitoring key support levels while others question whether the concentration in these seven names has reached an exhaustion point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2-Q3, PTSD Plan for 2027

Definium Therapeutics (NASDAQ:DFTX) used a company event to outline its late-stage development plans for DT120, an oral disintegrating tablet (ODT) formulation of LSD being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD), with an additional phase III study in post...

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

Definium Therapeutics, Inc. (Nasdaq: DFTX) (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying...

Leerink Partners Issues Positive Forecast for Definium Therapeutics (NASDAQ:DFTX) Stock Price

Leerink Partners increased their price objective on Definium Therapeutics from $23.00 to $30.00 and gave the company an "outperform" rating in a report on Wednesday...

Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move

Definium Therapeutics stock rises after hours amid psychedelic sector rally following Trump's regulatory push.read more...

<ul class="summary-bullets"><li>Momentum across psychedelic stocks gained after Trump signed an exec order directing the FDA to accelerate review of psychedelic therapies and committed $50 million towards research.</li><li>The company said it holds standardized, stabilized GMP-compliant ibogaine doses in inventory in a market where access to clinical-grade material remains limited.</li><li>Through its investment in PsyLabs, Psyence has built a vertically integrated platform spanning sourcing in Africa through extraction, purification and pharma production.</li></ul>Shares of Psyence Biomedical (PBM) surged into the spotlight again on Monday after the company underscored its pharma-grade ibogaine inventory advantage just as a new White House order boosted momentum behind psychedelic medicine research.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has logged a three-day winning streak, gaining 182% over the same period.&nbsp;<h2 class="st-heading-2">PBM Targets Global Ibogaine Supply Gap</h2>Psyence Biomedical said on Monday that it currently holds standardized, stabilized and Good Manufacturing Practice (GMP)-compliant ibogaine doses in inventory in a market where access to pharma-grade material remains limited and fragmented.Through its investment in PsyLabs, the company has built an integrated platform spanning sourcing at origin in Africa through extraction, purification and pharmaceutical production.&nbsp;“With limited GMP-grade ibogaine available globally, infrastructure and supply capabilities are the differentiator,” CEO Jody Aufrichtig said. “Our Company is positioned not only to support our own programs, but to enable the broader ecosystem as interest in ibogaine continues to grow.”The company added that its vertically integrated platform can reduce delays tied in supply constraints that have historically slowed progress in ibogaine-based clinical research.<h2 class="st-heading-2">PBM Rides FDA Psychedelic Review Momentum</h2>The supply update comes shortly after U.S. President Donald Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite review of psychedelic medicines, including ibogaine, while committing $50 million in funding toward related clinical-research programs.At the Oval Office signing ceremony, Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence, particularly for veterans with serious mental-health conditions.&nbsp;Ibogaine, a compound derived from a Central and West African shrub, remains classified as a Schedule I substance in the U.S. but has attracted growing attention for its potential role in treating post-traumatic stress disorder.The policy move triggered a broad rally across psychedelic-therapy developers. Shares of Enveric Biosciences (ENVB) surged 101%, Compass Pathways (CMPS) jumped 42%, Atai Life Sciences (ATAI) gained 22%, and Definium Therapeutics (DFTX) rose 2% on Monday.<h2 class="st-heading-2">PBM Builds Ibogaine Supply From Africa&nbsp;</h2>Operating near ibogaine’s natural source in Central and West Africa, PsyLabs has secured direct access to raw material with in-region processing to support traceable, reliable, and ethically sourced supply.&nbsp;Earlier this year, Psyence said it produced high-purity ibogaine hydrochloride from ethically sourced iboga bark and exported a GMP-compliant psilocybin product, NPX-5, to Australia for a Phase IIb trial in adjustment disorder among patients receiving palliative cancer care.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM was ‘extremely bullish’ amid an eye-watering 82,550% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_36a8236907.webp" alt="pbm ss.png" width="967" height="133"><figcaption>TSLA sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/LowDownDog12/message/650809854">said</a>, “Still holding my 5200 shares at 2.40. Bought believing this company could be the first to get ibogaine to market and still do.”<stembedurl>https://stocktwits.com/LowDownDog12/message/650809854</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/livetotradestox/message/650823742">noted</a> PBM's description of itself as the world’s only licensed pharma-grade ibogaine supplier at source level, and said: "Only sounds like a monopoly. At the very least a moat because of high barriers to entry for competitors."<stembedurl>https://stocktwits.com/livetotradestox/message/650823742</stembedurl>The stock has declined 48% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-rally-founder-bull-case-anktiva-breast-cancer-signal/cZBIIqmRICd">IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock Trips Into Spotlight Again: Rare Ibogaine Supply Edge Gets Boost From Trump’s Psychedelic Push

PBM stock extended its rally to a three-day winning streak, gaining about 182% over the period as investors focused on supply benefits in the ibogaine ecosystem.

Equity

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric...

<ul class="summary-bullets"><li>Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares.</li><li>Atai is now preparing for its investigational psychedelic drug BPL-003 to enter a late-stage trial this quarter.</li><li>Further, data from Atai’s mid-stage trial of VLS-01 in treatment-resistant depression is expected in the second half of 2026.</li></ul> Shares of AtaiBeckley Inc. (ATAI) surged 28% on Monday and are on track for their best single-day gain if the rally holds, following analyst price target hikes and growing optimism across the psychedelic drug sector after President Trump signed an executive order to accelerate research in the field.Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, while also committing $50 million to federal research into the psychedelic compound called ibogaine.The move boosted shares of companies including Definium Therapeutics (DFTX), Compass Pathways (CMPS), Enveric BioSciences (ENVB), and Psyence Biomedical (PBM), among others.<h2 class="st-heading-2">Wall Street Boost</h2>Separately, Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on the shares. Atai is now preparing for BPL-003 to enter a late-stage trial this quarter. The investigational drug is a fast-acting psychedelic designed for treatment-resistant depression (TRD) and alcohol use disorder.The analyst now expects the company to price BPL-003 at a net annual price of $30,000 at launch, in line with Janssen Pharmaceuticals's Spravato nasal spray already approved for treatment-resistant depression. Further, data from Atai’s mid-stage trial of VLS-01 in TRD is expected in the second half of 2026, the analyst noted.Guggenheim, meanwhile, raised the firm's price target on AtaiBeckley to $16 from $11 and kept a ‘Buy’ rating on the shares on Friday. The firm said that it recently met with Atai management, which reinforced its "conviction" in the BPL-003 program heading into late-stage initiation this quarter, the analyst told investors.According to data from Koyfin, all 14 analysts covering ATAI rate it ‘Buy’ or higher. The 12-month average price target on the stock is $13.83, representing a potential upside of about 166% from current trading levels.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ATAI stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user expressed optimism about the stocks of psychedelic drug developers including ATAI to “trend up for a while.” “This will be a good ride,” they said.<stembedurl>https://www.stocktwits.com/twiggs462/message/650773904</stembedurl>Another user cheered Atai’s great assets and voiced hopes for further rallies in future.<stembedurl>https://www.stocktwits.com/brunoq14/message/650772195</stembedurl><a href="https://stocktwits.com/symbol/ATAI">ATAI stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/agio-stock-slumps-whats-the-novo-connection/cZBd0tMRIzi">AGIO Stock Slumps 25% – What’s The Novo Connection?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ATAI Stock Soars On Track For Best Day On Trump Psychedelics Push And Wall Street Cheers

Trump on Saturday signed an executive order instructing the U.S. Food and Drug Administration to expedite the review of psychedelic drugs, spurring a rally among psychedelic drug developer stocks. 

Definium Therapeutics (NASDAQ:DFTX) Hits New 52-Week High  - Still a Buy?

Definium Therapeutics (NASDAQ:DFTX) Reaches New 1-Year High - Here's Why...

<ul class="summary-bullets"><li>Trump signed an executive order directing agencies to speed psychedelic research and approvals, alongside $50 million in federal funding for treatments such as ibogaine.</li><li>FDA Commissioner Marty Makary said aligned therapies could move through review timelines in weeks.</li><li>Koyfin consensus estimates suggest CMPS currently offers the larger implied upside, with 227% potential from recent levels, compared with about 62% for DFTX.</li></ul>A new White House push to fast-track psychedelic therapies has put Definium Therapeutics (DFTX) and Compass Pathways (CMPS) back in the spotlight, but analyst estimates suggest one may have significantly more upside from the policy shift.Both companies are advancing late-stage psychedelic therapies targeting psychiatric conditions, including depression, anxiety and post-traumatic stress disorder, placing them among the most directly exposed drug developers following the latest policy move.<a href="https://stocktwits.com/symbol/DFTX">DFTC stock</a> just posted its third straight week of gains, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">CMPS</a> ended last week 20% higher.&nbsp;<h2 class="st-heading-2">White House Pushes Speedy Psychedelic Research</h2>Over the weekend, U.S. President Donald Trump signed an executive order directing federal agencies to accelerate research, regulatory review and treatment access pathways tied to psychedelic medicines, including ibogaine, while committing $50 million in federal funding toward related clinical research.Trump said emerging psychedelic therapies could have a “tremendous impact” if supported by clinical evidence and emphasized their potential role in addressing serious mental-health conditions affecting veterans and other patients.Health Secretary Robert F. Kennedy Jr. said the initiative aims to remove barriers limiting research into psychiatric therapies, while FDA Commissioner Marty Makary said at the Oval Office that certain psychedelic medicines aligned with national priorities could move through regulatory review timelines within weeks and not over a year.Although ibogaine was the only psychedelic referenced directly in the executive order, Definium’ LSD-based DT120 and Compass’ psilocybin therapy COMP360 are already advancing through late-stage clinical trials in the U.S. for major psychiatric indications.<h2 class="st-heading-2">CMPS Emerges As Higher-Upside Psychedelic Bet</h2>Consensus estimates compiled by Koyfin suggest that Compass Pathways currently offers the larger implied upside from recent levels.DFTX holds a 12-month average analyst price target of $36.67, implying a 62% upside from current levels, with 12 analysts rating the stock ‘Buy’ and four rating it ‘Strong Buy’.Meanwhile, CMPS carries a 12-month average analyst price target of $21.75, implying a 227% upside, with eight analysts rating the stock ‘Buy’, three rating it ‘Strong Buy’, and one rating it ‘Hold’, pointing to a substantially wider valuation runway from current levels.<h2 class="st-heading-2">Definium Positions DT120 For Regulatory Push</h2>Definium Therapeutics responded to the executive order and said: “A science-driven framework that supports rigorous evaluation, responsible access, and faster translation of innovation into care is essential, and the FDA’s evidence-based approval process provides the most effective path to safely delivering these therapies to patients.”The company is developing DT120, a pharmaceutical version of LSD, in late-stage clinical trials for generalized anxiety disorder (GAD) and major depressive disorder, with results from three large Phase 3 studies expected this year. The treatment has already received FDA Breakthrough Therapy Designation for anxiety.After initial reports of the executive order surfaced, Stifel initiated coverage with a ‘Buy’ rating and a $30 price target, citing DT120’s probability-of-success outlook in GAD. The firm also noted that Definium has the largest market cap among psychedelic-drug developers but said the sector remains broadly undervalued and is likely to produce multiple winners.<h2 class="st-heading-2">COMP360 Targets Depression And PTSD Markets</h2>Compass Pathways also welcomed the executive order, noting that about four million Americans living with treatment-resistant depression and 13 million with PTSD have seen limited innovation for decades. “With today’s Executive Order including the potential for accelerated regulatory and rescheduling processes, should COMP360 be approved, we will be ready to make this treatment available to patients,” the company said in a statement on Saturday.COMP360 has already produced two positive Phase 3 trials showing statistically significant improvement in depressive symptoms with effects appearing as early as one day after administration and durability lasting at least six months after one or two doses among responding patients.Compass is currently working with the FDA on a rolling submission strategy for treatment-resistant depression and is advancing additional development in post-traumatic stress disorder after receiving clearance to begin a Phase 2b/3 study.<h2 class="st-heading-2">How Do Retail Traders Feel About DFTX, CMPS?</h2>On Stocktwits, retail sentiment for both DFTX and CMPS was ‘extremely bullish’ amid ‘extremely high’ message volume.One user&nbsp;<a href="https://stocktwits.com/MichaelNaussCMT/message/650733439">expects</a> a “flurry of upgrades” for DFTX stock and said, “see you all on the moon”<stembedurl>https://stocktwits.com/MichaelNaussCMT/message/650733439</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/stevenryl86/message/650739263">noted</a> that CMPS is “the only one at late stage, and not to mentioned on the breakthrough designation. Multiple Phase 3&nbsp; and consistent success and closest to approval.”<stembedurl>https://stocktwits.com/stevenryl86/message/650739263</stembedurl>While DFTX stock has surged nearly 300% over the past year, CMPS has more than doubled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-pushes-back-ford-ceo-byd-best-ev-rival-limiting-factor-china/cZB5z15RIyW">Tesla CEO Elon Musk Pushes Back After Ford CEO Calls BYD Best EV Rival — Points To Key 'Limiting Factor' In China</a>

While DFTX stock has surged nearly 300% over the past year, CMPS has more than doubled over the same period. (Photo credit: Getty Images)

DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?

Although ibogaine was the only therapy named in the order, Definium’s DT120 and Compass’ COMP360 treatments are already in late-stage U.S. trials for major psychiatric conditions.

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

Definium Therapeutics, Inc. (Definium or the Company), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and...

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

DFTX
Definium Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DFTX News

DFTXDefinium Therapeutics Inc.